A detailed history of Daiwa Securities Group Inc. transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 175 shares of CABA stock, worth $693. This represents 0.0% of its overall portfolio holdings.

Number of Shares
175
Previous 175 -0.0%
Holding current value
$693
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 31, 2024

BUY
$12.21 - $23.36 $2,136 - $4,088
175 New
175 $4,000
Q4 2020

Feb 04, 2021

BUY
$9.81 - $15.8 $441 - $711
45 New
45 $1,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $115M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.